Prédiction de la toxicité de Docetaxel par le dosage de l'Alpha-1-Glycoprotéine Acide dans le cancer du sein

Abstract

Background: Docetaxel is a cytotoxic drug used in different types of cancer. However, the tolerance is marked by hematological toxicity especially neutropenia. Distribution of Docetaxel is assured by lipoproteins, albumin and α1-acid glycoprotein. It is demonstrated that docetaxel clearance was related to α1-acid glycoprotein level. Increased estrogen level is associated with decreased plasmatic concentration of α1-acid glycoprotein, and unbound docetaxel is correlated with α1-acid glycoprotein. In fact, this study solves the hypothesis that women who have a decreased levels of α1-acid glycoprotein are more exposed to develop severe toxicities of docetaxel chemotherapy. Patients: Women diagnosed with breast cancer undergoing chemotherapy by docetaxel Methods: Pretreatment dosage of α1-acid glycoprotein and check in of the neutropenia and adverse events of Docetaxel Results: Thirty patients are included in the study, 23 patients (76,66%) developed neutropenia. α1-acid glycoprotein is correlated to neutropenia (Khi2 18.3, p<0,0001) Conclusion: α1-acid glycoprotein Level can be considered as independent factor to Docetaxel toxicity, results to be confirmed by more investigations with large sample.